Tingley Whittemore sold $5K of TNYA

Tingley Whittemore (Chief Medical Officer) sold 7,424 shares of Tenaya Therapeutics, Inc. (TNYA) at $0.71 across 4 trades on 2026-08-17.

Original reporting
SEC EDGAR · Tingley Whittemore
Published Aug 18, 2026, 12:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TNYA
Neutral
medium confidence
Mentioned
$TNYA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNYANeutralLow
01

Why it matters

An insider open-market sale can slightly pressure sentiment, but without accompanying guidance, trial results, financing, or regulatory updates, it is unlikely to drive a sustained repricing.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the disclosure alone is not a fundamental catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on prior grants, option exercises, or total insider ownership changes beyond the post-trade share count.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-17 after-hours; transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Tenaya Therapeutics, Inc.

Company-level read

Ticker impact

$TNYANeutralMedium confidence
Context

Tenaya Therapeutics insider Form 4 shows CMO Tingley Whittemore sold 7,424 shares at $0.7098 on 2026-08-17.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or other disclosures.

Evidence & confidence

This is a routine Form 4 transaction with small dollar value and no 10b5-1 plan stated, but it is not accompanied by new operating or regulatory information.

Market effects

No clear sector read-through from a single insider sale at a small biotech.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to company outlook (taxes, diversification, or routine compensation), so it may not signal negative fundamentals.

Key entities

  • Tenaya Therapeutics, Inc.

    Subject of the Form 4 insider sale by its Chief Medical Officer.

  • Tingley Whittemore

    Chief Medical Officer who sold 7,424 shares at $0.7098 on 2026-08-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TNYAMed

Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

$TNYAMed

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.

$TNYAMed

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional

$TNYAMedAI 9/10

Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM

Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.